Login to Your Account

Innovation on Both Sides

First in Class vs. Best in Class; Not the Same Old R&D Debate

By Jennifer Boggs

Monday, February 21, 2011
It would be easy to view Merck & Co. Inc.'s recent decision to bail on two novel-target collaborations with Galapagos NV as a troubling sign that the industry is shying away from innovation and putting more investment dollars behind the safer, tried-and-true mechanisms of earlier blockbusters. (See BioWorld Today, Feb. 9, 2011.)

To continue reading subscribe now to BioWorld Insight

Learn More about BioWorld Insight

Already a subscriber? Sign In or Buy now to activate your subscription